Oseltamivir phosphate granules and preparation method thereof

Through improved formula and spray drying technology, oseltamivir phosphate granules with high stability and sustained release are prepared, which solves the problem of insufficient stability and sustained release of drugs in the prior art, and achieves a more uniform Drug release and prolonged half-life improve patients' medication compliance.

CN118903024AInactive Publication Date: 2024-11-08GUANGDONG RUIXING PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411244383.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing oseltamivir phosphate granules have problems with insufficient drug stability and sustained release, which leads to easy degradation of drugs and frequent medication.

Method used

Using improved formulation and preparation processes, including the use of oseltamivir phosphate, erythritol, soluble starch, dextrin, povidone and other components, the preparation of stable sustained release particles through spray drying technology to ensure that the drug is Uniform wet particles are formed under the collision of high-temperature and low-temperature droplets, and stable oseltamivir phosphate granules are obtained by drying.

Benefits of technology

It significantly improves the uniformity and stability of the content of oseltamivir phosphate granules, extends the drug release rate and half-life, reduces the number of medications taken by patients, and improves the patient's compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005030227900000021
    Figure BDA0005030227900000021
  • Figure BDA0005030227900000022
    Figure BDA0005030227900000022
  • Figure BDA0005030227900000032
    Figure BDA0005030227900000032
Patent Text Reader

Abstract

The invention relates to oseltamivir phosphate granules and a preparation method thereof, and belongs to the field of pharmaceutical preparations. The oseltamivir phosphate granules comprise the following components in percentage by weight: 3%-5% of oseltamivir phosphate, 80%-85% of erythritol, 3%-5% of soluble starch, 2%-3% of dextrin, 2%-5% of povidone, 1%-2% of acesulfame potassium, 1%-2% of saccharin sodium, 0.3%-1% of polyglycerol fatty acid ester, 0.3%-1% of medium chain triglyceride, 0.2%-1% of silicon dioxide and 0.4%-2% of essence. By improving the formula of the existing oseltamivir phosphate granules and optimizing the preparation process, the content uniformity and stability of the granules prepared by the preparation process are superior to those of the oseltamivir phosphate granules in the prior art. The oseltamivir phosphate granules disclosed by the invention are slow in release speed and long in half-life period in a test rabbit body, and the half-life period is obviously longer than that of a reference agent, so that after the oseltamivir phosphate granules are clinically used, the medicine taking times of a patient can be easily reduced, and the compliance of the patient can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to oseltamivir phosphate granules and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. Background Art

[0002] Oseltamivir phosphate is one of the effective drugs against avian influenza, influenza A (H1N1) virus and influenza B virus. Chinese chemical name: (3R, 4R, 5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate.

[0003] Currently, the commercially available oseltamivir phosphate includes oseltamivir phosphate capsules and oseltamivir phosphate granules, but the granules have drug stability issues. During the preparation of the preparation, oseltamivir phosphate is prone to degradation and other reactions, resulting in an increase in impurities, which increases the risk of the preparation.

[0004] In addition, adults generally take existing oseltamivir phosphate granules twice a day, 5 bags (i.e. 75 mg) each time, for 5 consecutive days; this has the disadvantages of a large single dose and frequent medication.

[0005] Therefore, during the research process, it is necessary to consider improving the stability and sustained release of the existing oseltamivir phosphate.

[0006] Based on this, the present invention is proposed. Summary of the invention

[0007] In view of the deficiencies in the prior art, the present invention provides an oseltamivir phosphate granule and a preparation method thereof. The specific technical scheme is as follows:

[0008] An oseltamivir phosphate granule comprises the following components in percentage by weight:

[0009] Oseltamivir phosphate 3% to 5%;

[0010]

[0011] The sum of the weight percentages of the above components is 100%.

[0012] Furthermore, an oseltamivir phosphate granule comprises the following components in weight percentage:

[0013]

[0014]

[0015] Furthermore, an oseltamivir phosphate granule comprises the following components in weight percentage:

[0016] Furthermore, an oseltamivir phosphate granule comprises the following components in weight percentage:

[0017]

[0018]

[0019] Furthermore, the povidone is povidone K30.

[0020] Furthermore, the dextrin is sulfobutyl-β-cyclodextrin.

[0021] Furthermore, the mass ratio of erythritol to soluble starch is 27:1.

[0022] Furthermore, the weight percentage of the soluble starch is greater than or equal to the weight percentage of dextrin.

[0023] Furthermore, a method for preparing oseltamivir phosphate granules comprises the following steps:

[0024] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, dextrin, povidone, acesulfame potassium, saccharin sodium, polyglycerol fatty acid ester, medium chain triglyceride, silicon dioxide, and flavor according to the formula;

[0025] Step 2, dissolving soluble starch in hot water to obtain a soluble starch aqueous solution, then cooling the solution to 55° C. to 60° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution;

[0026] Step 3, after mixing and grinding erythritol and dextrin, a first mixed powder is obtained; the first mixed powder is heated to 120-125° C., and the first mixed liquid is frozen to 0° C.; compressed air is used to transport the heated first mixed powder to a spray drying tower for atomization, and the frozen first mixed liquid is pumped into the spray drying tower for atomization through an atomizing nozzle, and the atomized first mixed powder and the atomized first mixed liquid are arranged oppositely in the spray drying tower, and the atomized first mixed powder and the atomized first mixed liquid are combined into wet particles in the spray drying tower, and the wet particles are dried on a fluidized bed below the spray drying tower to obtain first dry particles; the first dry particles are granulated to obtain second dry particles;

[0027] Step 4, dissolving povidone in water to prepare a povidone aqueous solution, uniformly mixing the second dry granules, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0028] Soluble starch is a white or off-white powder, odorless and tasteless, insoluble in cold water, but can become a transparent solution in hot water and does not freeze after cooling. Since oseltamivir phosphate is also dissolved in the soluble starch aqueous solution, it forms low-temperature droplets under the action of the atomizer.

[0029] Erythritol melts into liquid at 120-125°C and mixes with dextrin. Under the atomization of compressed air, it takes dextrin particles as carriers to form a large number of high-temperature droplets. When the high-temperature droplets collide with the low-temperature droplets, the high-temperature droplets cool down rapidly to precipitate erythritol, and the low-temperature droplets heat up rapidly to eventually form a large number of tiny, uniform wet particles. The wet particles are dried to obtain first dry particles containing oseltamivir phosphate, erythritol, soluble starch and dextrin. The first dry particles have good stability and are sustained-release particles.

[0030] Furthermore, in step 2, the temperature of the hot water used to dissolve the soluble starch is 80-100° C., and the amount used is 2-2.5 times that of the soluble starch; in step 4, the mass fraction of the polyvidone aqueous solution is 5-10%.

[0031] Beneficial effects of the present invention:

[0032] 1. The present invention improves the formula of the existing oseltamivir phosphate granules and optimizes the preparation process. The granules prepared by the preparation process have better content uniformity and stability than the oseltamivir phosphate granules in the prior art.

[0033] 2. The release rate of the oseltamivir phosphate granules of the present invention is slow, and the half-life in the test rabbit is long, which is significantly longer than that of the reference agent, indicating that after the oseltamivir phosphate granules of the present invention are used clinically, it is easy for patients to reduce the number of medications and improve patient compliance. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0035] Example 1

[0036] Recipe 1

[0037] Raw material name content(%) Oseltamivir phosphate 3 Erythritol 81 Soluble starch 3 Sulfonbutyl-β-cyclodextrin 2 Povidone K30 2 Acesulfame Potassium 2 Saccharin Sodium 2 Polyglycerol fatty acid esters 1 Medium Chain Triglycerides 1 Silicon dioxide 1 Assorted fruit flavors 2

[0038] The preparation method of the oseltamivir phosphate granules comprises the following steps:

[0039] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, povidone K30, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide, and assorted fruit flavors according to the formula;

[0040] Step 2, dissolving soluble starch in hot water at a temperature of 80° C., the amount of hot water used is twice that of the soluble starch, to obtain a soluble starch aqueous solution, then cooling to 55° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution;

[0041] Step 3, after mixing and grinding erythritol and sulfobutyl-β-cyclodextrin, a first mixed powder is obtained; the first mixed powder is heated to 120° C., and the first mixed solution is frozen to 0° C.; compressed air is used to transport the heated first mixed powder to a spray drying tower for atomization, and the frozen first mixed solution is pumped into the spray drying tower for atomization through an atomizing nozzle, and the atomized first mixed powder and the atomized first mixed solution are arranged oppositely in the spray drying tower, and the atomized first mixed powder and the atomized first mixed solution are combined into wet particles in the spray drying tower, and the wet particles are dried on a fluidized bed below the spray drying tower to obtain first dry particles; the first dry particles are granulated to obtain second dry particles;

[0042] Step 4, dissolving povidone in water to prepare a 5% povidone aqueous solution by mass, uniformly mixing the second dry granules, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and assorted fruit flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0043] Example 2

[0044] Recipe 2

[0045] Raw material name content(%) Oseltamivir phosphate 4 Erythritol 81 Soluble starch 3 Sulfonbutyl-β-cyclodextrin 3 Povidone K30 3.5 Acesulfame Potassium 1.5 Saccharin Sodium 1.5 Polyglycerol fatty acid esters 0.5 Medium Chain Triglycerides 0.5 Silicon dioxide 0.5 Assorted fruit flavors 1

[0046] The preparation method of the oseltamivir phosphate granules comprises the following steps:

[0047] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, povidone K30, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide, and assorted fruit flavors according to the formula;

[0048] Step 2, dissolving soluble starch in hot water at a temperature of 90° C., and the amount of hot water used is twice that of the soluble starch, to obtain a soluble starch aqueous solution, and then cooling the solution to 55° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution;

[0049] Step 3, after mixing and grinding erythritol and sulfobutyl-β-cyclodextrin, a first mixed powder is obtained; the first mixed powder is heated to 122° C., and the first mixed solution is frozen to 0° C.; compressed air is used to transport the heated first mixed powder to a spray drying tower for atomization, and the frozen first mixed solution is pumped into the spray drying tower for atomization through an atomizing nozzle, and the atomized first mixed powder and the atomized first mixed solution are arranged oppositely in the spray drying tower, and the atomized first mixed powder and the atomized first mixed solution are combined into wet particles in the spray drying tower, and the wet particles are dried on a fluidized bed below the spray drying tower to obtain first dry particles; the first dry particles are granulated to obtain second dry particles;

[0050] Step 4, dissolving povidone in water to prepare a povidone aqueous solution with a mass fraction of 7%, uniformly mixing the second dry granules, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and assorted fruit flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0051] Example 3

[0052] Recipe 3

[0053] Raw material name content(%) Oseltamivir phosphate 5 Erythritol 81 Soluble starch 3 Sulfonbutyl-β-cyclodextrin 2.8 Povidone K30 5 Acesulfame Potassium 1 Saccharin Sodium 1 Polyglycerol fatty acid esters 0.3 Medium Chain Triglycerides 0.3 Silicon dioxide 0.2 Assorted fruit flavors 0.4

[0054] The preparation method of the oseltamivir phosphate granules comprises the following steps:

[0055] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, povidone K30, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide, and assorted fruit flavors according to the formula;

[0056] Step 2, dissolving soluble starch in hot water at a temperature of 100° C., and the amount of hot water used is 2.5 times that of the soluble starch, to obtain a soluble starch aqueous solution, and then cooling to 60° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution;

[0057] Step 3, after mixing and grinding erythritol and sulfobutyl-β-cyclodextrin, a first mixed powder is obtained; the first mixed powder is heated to 125° C., and the first mixed solution is frozen to 0° C.; compressed air is used to transport the heated first mixed powder to a spray drying tower for atomization, and the frozen first mixed solution is pumped into the spray drying tower for atomization through an atomizing nozzle, and the atomized first mixed powder and the atomized first mixed solution are arranged oppositely in the spray drying tower, and the atomized first mixed powder and the atomized first mixed solution are combined into wet particles in the spray drying tower, and the wet particles are dried on a fluidized bed below the spray drying tower to obtain first dry particles; the first dry particles are granulated to obtain second dry particles;

[0058] Step 4, dissolving povidone in water to prepare a povidone aqueous solution with a mass fraction of 10%, uniformly mixing the second dry granules, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and assorted fruit flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0059] Comparative Example 1

[0060] The only difference between this example and Example 1 is that mannitol is used instead of erythritol in this example, and the rest remains unchanged.

[0061] Comparative Example 2

[0062] The only difference between this example and Example 1 is that soluble starch is used instead of erythritol in this example, and the rest remains unchanged.

[0063] Comparative Example 3

[0064] The only difference between this example and Example 1 is that erythritol is used instead of soluble starch in this example, and the rest remains unchanged.

[0065] Comparative Example 4

[0066] The only difference between this example and Example 1 is that β-cyclodextrin is used instead of sulfobutyl-β-cyclodextrin in this example, and the rest remains unchanged.

[0067] Comparative Example 5

[0068] The difference between this example and Example 1 is that the preparation method is different; the preparation method of this example is as follows:

[0069] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, povidone K30, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide, and assorted fruit flavors according to the formula;

[0070] Step 2, dissolving povidone in water to prepare a 5% povidone aqueous solution by mass, uniformly mixing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and assorted fruit flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0071] Comparative Example 6

[0072] The difference between this example and Example 1 is that the preparation method is different; the preparation method of this example is as follows:

[0073] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, povidone K30, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide, and assorted fruit flavors according to the formula;

[0074] Step 2, dissolving soluble starch in hot water at a temperature of 80° C., the amount of hot water used is twice that of the soluble starch, to obtain a soluble starch aqueous solution, then cooling to 55° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution;

[0075] Step 3, heating erythritol to 120° C. and freezing the first mixed liquid to 0° C.; using compressed air to transport the heated erythritol to a spray drying tower for atomization; the frozen first mixed liquid is pumped into the spray drying tower for atomization through an atomizing nozzle; the atomized erythritol and the atomized first mixed liquid are arranged in opposite directions in the spray drying tower; the atomized erythritol and the atomized first mixed liquid are combined in the spray drying tower to form second mixed particles; the second mixed particles are dried on a fluidized bed below the spray drying tower to obtain third dry particles; the third dry particles are granulated to obtain fourth dry particles;

[0076] Step 4, dissolving povidone in water to prepare a 5% povidone aqueous solution by mass, uniformly mixing the fourth dry granules, sulfobutyl-β-cyclodextrin, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and assorted fruit flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0077] Comparative Example 7

[0078] The difference between this example and Example 1 is that the preparation method is different; the preparation method of this example is as follows:

[0079] Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, sulfobutyl-β-cyclodextrin, povidone K30, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide, and assorted fruit flavors according to the formula;

[0080] Step 2, dissolving soluble starch in hot water at a temperature of 80° C., the amount of hot water used is twice that of the soluble starch, to obtain a soluble starch aqueous solution, then cooling to 55° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution;

[0081] Step 3, after mixing and grinding erythritol and sulfobutyl-β-cyclodextrin, a first mixed powder is obtained; the first mixed powder is heated to 120° C., and the first mixed solution is cooled to 15° C.; compressed air is used to transport the heated first mixed powder to a spray drying tower for atomization, and the cooled first mixed solution is pumped into the spray drying tower for atomization through an atomizing nozzle, and the atomized first mixed powder and the atomized first mixed solution are arranged oppositely in the spray drying tower, and the atomized first mixed powder and the atomized first mixed solution are combined into wet particles in the spray drying tower, and the wet particles are dried on a fluidized bed below the spray drying tower to obtain first dry particles; the first dry particles are granulated to obtain second dry particles;

[0082] Step 4, dissolving povidone in water to prepare a 5% povidone aqueous solution by mass, uniformly mixing the second dry granules, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and assorted fruit flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

[0083] Test Example 1

[0084] Table 1

[0085]

[0086]

[0087] The preparation process in this example is the same as that in Example 1, and the formulations are respectively carried out according to Table 1.

[0088] 1. Content uniformity test

[0089] The content of oseltamivir phosphate in oseltamivir phosphate granules was determined by HPLC, and the content uniformity was calculated. The results are shown in Table 2:

[0090] Table 2

[0091] Content uniformity RSD value (%) Example 1 3.27 Example 2 3.95 Example 3 4.11 Comparative Example 1 1.78 Comparative Example 2 2.65 Comparative Example 3 9.22 Comparative Example 4 4.27 Comparative Example 5 4.91 Comparative Example 6 4.37 Recipe 21 7.58 Recipe 22 11.06 Recipe 23 4.38 Recipe 24 3.98

[0092] In the present invention, the weight percentage of the soluble starch needs to be greater than or equal to the weight percentage of sulfobutyl-β-cyclodextrin, otherwise it will significantly affect the content uniformity of the granules.

[0093] 2. Stability Investigation

[0094] The content of relevant substances and active ingredients was detected by high performance liquid chromatography (refer to the General Rules of Part IV of the 2020 edition of the Chinese Pharmacopoeia 0512), and the peak area was calculated using the external standard method; the results are shown in Table 3:

[0095] Table 3

[0096]

[0097]

[0098] The high humidity environment in Table 3 is an environment of 35°C ± 1°C and a relative humidity of 80% ± 2%.

[0099] As shown in Table 3, when erythritol and soluble starch are used as fillers, first dry particles must be prepared. If a direct mixing method is used, it is easy to cause degradation of oseltamivir phosphate. However, preparing first dry particles first and then mixing can solve the defect of poor stability. In particular, when the mass ratio of erythritol to soluble starch is 27:1, the system is more stable, which can significantly improve the stability of oseltamivir phosphate granules.

[0100] 3. Sustained-release study

[0101] 48 experimental rabbits were randomly divided into groups, fasted for 12 hours before the experiment, and randomized crossover test was performed. Oseltamivir phosphate granules were orally administered at a single dose of 20 mg / kg body weight. The rabbits were weighed after administration.

[0102] The time before administration was recorded as zero. Blood was collected at 10min, 20min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, and 12h after administration, with 1.5ml of blood collected each time. After blood collection, plasma was separated. Liquid chromatography tandem mass spectrometry (LC-MS / MS) was used for detection, and the half-life T was calculated. 1 / 2 The results are shown in Table 4:

[0103] Table 4

[0104] <![CDATA[T 1 / 2 (h)]]> Example 1 9.82 Comparative Example 4 7.95 Comparative Example 5 5.19 Comparative Example 6 5.88 Comparative Example 7 6.04 Reference ratio 5.63

[0105] The reference agent used in the reference example is a commercially available drug with the national medicine standard H20080763. The test results show that the oseltamivir phosphate granules of the present invention are prepared by mixing erythritol and sulfobutyl-β-cyclodextrin at high temperature to form high-temperature material droplets, dissolving oseltamivir phosphate and soluble starch in water to form low-temperature material droplets, granulating by collision of high-temperature material droplets and low-temperature material droplets, and finally drying to form stable sustained-release granules; the oseltamivir phosphate granules prepared with the sustained-release granules as the core and sulfobutyl-β-cyclodextrin as the auxiliary have good sustained-release properties, and the half-life reaches 9.82h, which is significantly better than comparative examples 4 to 7 and the reference example.

[0106] In the above embodiments, the drying temperature in all steps is 55-65°C.

[0107] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An oseltamivir phosphate granule, It is characterized in that The composition includes the following weight percentages: The sum of the weight percentages of the above components is 100%.

2. The oseltamivir phosphate granules according to claim 1, It is characterized in that The composition includes the following weight percentages:

3. The oseltamivir phosphate granules according to claim 1, It is characterized in that The composition includes the following weight percentages:

4. The oseltamivir phosphate granules according to claim 1, It is characterized in that The composition includes the following weight percentages:

5. The oseltamivir phosphate granules according to claim 1, Features: The povidone is povidone K30.

6. The oseltamivir phosphate granules according to claim 1, Features: The dextrin is sulfobutyl-β-cyclodextrin.

7. The oseltamivir phosphate granules according to claim 1, Features: The mass ratio of erythritol to soluble starch is 27:

1.

8. The oseltamivir phosphate granules according to claim 1, Features: The weight percentage of the soluble starch is greater than or equal to the weight percentage of dextrin.

9. A method for preparing oseltamivir phosphate granules according to any one of claims 1 to 8, It is characterized in that The following steps are involved: Step 1, weighing oseltamivir phosphate, erythritol, soluble starch, dextrin, povidone, acesulfame potassium, saccharin sodium, polyglycerol fatty acid ester, medium chain triglyceride, silicon dioxide, and flavor according to the formula; Step 2, dissolving soluble starch in hot water to obtain a soluble starch aqueous solution, then cooling the solution to 55° C. to 60° C., adding oseltamivir phosphate to the soluble starch aqueous solution, and stirring to obtain a first mixed solution; Step 3, after mixing and grinding erythritol and dextrin, a first mixed powder is obtained; the first mixed powder is heated to 120-125° C., and the first mixed liquid is frozen to 0° C.; compressed air is used to transport the heated first mixed powder to a spray drying tower for atomization, and the frozen first mixed liquid is pumped into the spray drying tower for atomization through an atomizing nozzle, and the atomized first mixed powder and the atomized first mixed liquid are arranged oppositely in the spray drying tower, and the atomized first mixed powder and the atomized first mixed liquid are combined into wet particles in the spray drying tower, and the wet particles are dried on a fluidized bed below the spray drying tower to obtain first dry particles; the first dry particles are granulated to obtain second dry particles; Step 4, dissolving povidone in water to prepare a povidone aqueous solution, uniformly mixing the second dry granules, acesulfame potassium, saccharin sodium, polyglycerol fatty acid esters, medium-chain triglycerides, silicon dioxide and flavors, adding the povidone aqueous solution for wet granulation, drying, and granulating to obtain the oseltamivir phosphate granules.

10. The method for preparing oseltamivir phosphate granules according to claim 9, Features: In step 2, the temperature of the hot water used to dissolve the soluble starch is 80-100° C., and the amount used is 2-2.5 times that of the soluble starch; in step 4, the mass fraction of the polyvidone aqueous solution is 5-10%.

Citation Information

Patent Citations

  • Oseltamivir phosphate dry syrup and preparation method thereof

    CN112587484A

  • Preparation method of oseltamivir phosphate dry suspension

    CN113730358A